首页> 美国卫生研究院文献>Scientific Reports >A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy
【2h】

A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy

机译:体外冲击波碎石术对药物排除治疗有益效果的网络荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

We applied a newly introduced method, network meta-analysis, to re-evaluate the expulsion effect of drugs including tamsulosin, doxazosin, nifedipine, terazosin and rowatinex after extracorporeal shock wave lithotripsy (ESWL) as described in the literature. A systematic search was performed in Medline, Embase and Cochrane Library for articles published before March 2016. Twenty-six studies with 2775 patients were included. The primary outcome was the number of patients with successful stone expulsion. The data were subdivided into three groups according to duration of follow-up. A standard network model was established in each subgroup. In 15-day follow-up results, SUCRA outcome showed the ranking of effects was: doxazosin > tamsulosin > rowatinex > nifedipine > terazosin (88.6, 77.4, 58.6, 32.2 and 30.4, respectively). In 45-day follow-up results, SUCRA ranking was: tamsulosin > nifedipine > rowatinex (69.4, 67.2 and 62.6, respectively). In 90-day follow-up results, SUCRA ranking was: doxazosin > rowatinex > tamsulosin (84.1, 68.1 and 49.1, respectively). In conclusion, doxazosin and tamsulosin have potential to be the first choice for pharmacological therapy to promote the expulsion of urinary stone fragments after ESWL, with this doxazosin can improve the SFR in the long term, while tamsulosin may result more in accelerating the process of expulsion.
机译:我们采用了一种新引入的方法,即网络荟萃分析,以重新评估体外冲击波碎石术(ESWL)对坦洛新,多沙​​唑嗪,硝苯地平,特拉唑嗪和Rowatinex的驱逐作用。在Medline,Embase和Cochrane图书馆中进行了系统的检索,以查找2016年3月之前发表的文章。纳入了26项针对2775名患者的研究。主要结局是成功排石的患者人数。根据随访时间将数据分为三组。在每个子组中建立了一个标准的网络模型。在15天的随访结果中,SUCRA结果显示,其作用等级为:多沙唑嗪>坦索洛辛> rowatinex>硝苯地平>特拉唑嗪(分别为88.6、77.4、58.6、32.2和30.4)。在45天的随访结果中,SUCRA的排名为:坦洛新>硝苯地平>罗罗汀(分别为69.4、67.2和62.6)。在90天的随访结果中,SUCRA排名为:多沙唑嗪s> rowatinex>坦索罗辛(分别为84.1、68.1和49.1)。总之,多沙唑嗪和坦索罗辛有可能成为促进ESWL术后泌尿结石排出的药物治疗的首选,这种多沙唑嗪可以长期改善SFR,而坦索罗辛可能在加速排泄过程中起更大作用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号